FDA
-
-
-
-
-
-
-
Pelthos Therapeutics appoints Andrew Einhorn to board of directors
-
-
-
-
-
-
-
Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
-
-
-
-
-
-
-
Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

